T CELL MANUFACTURING COMPOSITIONS AND METHODS
The generation of antigen specific T cells by controlled ex vivo induction or expansion can provide highly specific and beneficial T cell therapies. The present disclosure provides T cell manufacturing methods and therapeutic T cell compositions which can be used for treating subjects with cancer and other conditions, diseases and disorders personal antigen specific T cell therapy..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Europäisches Patentamt - (2022) vom: 08. Sept. Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
VAN BUUREN MARIT M [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2022-09-08, Last update posted on www.tib.eu: 2024-04-10, Last updated: 2024-04-19 |
|---|
| Patentnummer: |
US2022280621 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA000409766 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA000409766 | ||
| 003 | DE-627 | ||
| 005 | 20240419122401.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240315s2022 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA000409766 | ||
| 035 | |a (EPA)US2022280621 | ||
| 035 | |a (EPA)73051205 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a VAN BUUREN MARIT M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a T CELL MANUFACTURING COMPOSITIONS AND METHODS |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2022-09-08, Last update posted on www.tib.eu: 2024-04-10, Last updated: 2024-04-19 | ||
| 520 | |a The generation of antigen specific T cells by controlled ex vivo induction or expansion can provide highly specific and beneficial T cell therapies. The present disclosure provides T cell manufacturing methods and therapeutic T cell compositions which can be used for treating subjects with cancer and other conditions, diseases and disorders personal antigen specific T cell therapy. | ||
| 650 | 4 | |a bio | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a LENKALA DIVYA REDDY |e verfasserin |4 aut | |
| 700 | 0 | |a KOHLER JESSICA |e verfasserin |4 aut | |
| 700 | 0 | |a BROWN FLAVIAN DUVALLE |e verfasserin |4 aut | |
| 700 | 0 | |a KUKSIN CHRISTINA MURPHY |e verfasserin |4 aut | |
| 700 | 0 | |a VAN DEN BERG JOOST HUIBERT |e verfasserin |4 aut | |
| 700 | 0 | |a DE BOER RENATE |e verfasserin |4 aut | |
| 700 | 0 | |a BAKKER NOOR |e verfasserin |4 aut | |
| 700 | 0 | |a SCHUMACHER TON |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2022) vom: 08. Sept. |
| 773 | 1 | 8 | |g year:2022 |g day:08 |g month:09 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/73051205/publication/US2022280621A1?q=US2022280621 |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 08 |c 09 | ||